Literature DB >> 19282772

Methylation of helicase-like transcription factor in serum of patients with colorectal cancer is an independent predictor of disease recurrence.

Andreas Herbst1, Maike Wallner, Konstanze Rahmig, Petra Stieber, Alexander Crispin, Rolf Lamerz, Frank T Kolligs.   

Abstract

BACKGROUND: CpG island hypermethylation is a common epigenetic event in colorectal cancer. The presence of simultaneous methylation of multiple genes is associated with poor prognosis in many types of tumours including colorectal cancer. We have shown earlier that the hypermethylation of the genes HLTF and HPP1/TPEF are independent prognostic serum markers in colorectal cancer identifying patients with increased risk of death. The purpose of this study was to analyse whether these factors also identify patients at risk of disease recurrence after curative surgery.
METHODS: Pretherapeutic sera of 106 patients curatively resected for colorectal cancer with known 5-year follow-ups were analysed for the presence of methylation of the genes HLTF and HPP1/TPEF.
RESULTS: HLTF serum methylation was associated with an increased risk of disease recurrence by a factor of 2.7 (95% confidence interval: 1.2-6.0; P=0.014). Multivariate analysis showed methylated HLTF serum DNA to be independently associated with poor outcome and a relative risk of disease recurrence of 2.5 (95% confidence interval: 1.1-5.6; P=0.023).
CONCLUSION: Here, we show for the first time that a DNA methylation-based surrogate marker can serve as a predictor of disease recurrence in colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19282772     DOI: 10.1097/MEG.0b013e328318ecf2

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  33 in total

Review 1.  Advances in epigenetic biomarker research in colorectal cancer.

Authors:  Xi Wang; Ye-Ye Kuang; Xiao-Tong Hu
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 2.  DNA methylation patterns as noninvasive biomarkers and targets of epigenetic therapies in colorectal cancer.

Authors:  Yutaka Hashimoto; Timothy J Zumwalt; Ajay Goel
Journal:  Epigenomics       Date:  2016-04-22       Impact factor: 4.778

3.  Heterogeneous DNA methylation contributes to tumorigenesis through inducing the loss of coexpression connectivity in colorectal cancer.

Authors:  Quan Wang; Peilin Jia; Feixiong Cheng; Zhongming Zhao
Journal:  Genes Chromosomes Cancer       Date:  2014-11-19       Impact factor: 5.006

4.  Detection of DNA hypermethylation in remote media of patients with colorectal cancer: new biomarkers for colorectal carcinoma.

Authors:  Andreas Herbst; Frank T Kolligs
Journal:  Tumour Biol       Date:  2012-02-24

Review 5.  The helicase-like transcription factor (HLTF) in cancer: loss of function or oncomorphic conversion of a tumor suppressor?

Authors:  Ludovic Dhont; Céline Mascaux; Alexandra Belayew
Journal:  Cell Mol Life Sci       Date:  2016-01       Impact factor: 9.261

Review 6.  Epigenetics of colorectal cancer: emerging circulating diagnostic and prognostic biomarkers.

Authors:  Elisa Danese; Martina Montagnana
Journal:  Ann Transl Med       Date:  2017-07

7.  Methylation of serum SST gene is an independent prognostic marker in colorectal cancer.

Authors:  Yanqun Liu; Min Hoe Chew; Chee Kian Tham; Choong Leong Tang; Simon Yk Ong; Yi Zhao
Journal:  Am J Cancer Res       Date:  2016-09-01       Impact factor: 6.166

8.  Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer.

Authors:  Mónica Castro; Laura Grau; Patricia Puerta; Liliana Gimenez; Julio Venditti; Silvia Quadrelli; Marta Sánchez-Carbayo
Journal:  J Transl Med       Date:  2010-09-17       Impact factor: 5.531

Review 9.  Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers.

Authors:  Yoshinaga Okugawa; William M Grady; Ajay Goel
Journal:  Gastroenterology       Date:  2015-07-26       Impact factor: 22.682

Review 10.  DNA methylation aberrancies delineate clinically distinct subsets of colorectal cancer and provide novel targets for epigenetic therapies.

Authors:  D J Weisenberger; G Liang; H-J Lenz
Journal:  Oncogene       Date:  2017-10-09       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.